Herne, Germany

Gertrud Hoetten

This inventor holds 1 USPTO granted patent. Top assignee: Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gertrud Hoetten. Retrieved from https://idiyas.com/inventor/gertrud-hoetten

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gertrud Hoetten: Innovator in Biotechnology

Introduction

Gertrud Hoetten is a notable inventor based in Herne, Germany. She has made significant contributions to the field of biotechnology, particularly in the area of growth and differentiation factors.

Latest Patents

Gertrud holds 1 patent related to a protein of the TGF-β family. This invention encompasses the DNA coding for the protein and a pharmaceutical composition that includes it. Her work is pivotal in advancing therapeutic applications in medicine.

Career Highlights

Gertrud is associated with Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH, where she applies her expertise in biotechnology. Her innovative approach has led to advancements in the understanding and application of growth factors.

Collaborations

Throughout her career, Gertrud has collaborated with esteemed colleagues, including Helge Neidhardt and Michael Paulista. These partnerships have fostered a collaborative environment that enhances research and development in her field.

Conclusion

Gertrud Hoetten's contributions to biotechnology exemplify the impact of innovative thinking in science. Her work continues to influence the development of new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…